Conference Correspondent  - ESMO 2018, ESMO

Germ-line mutations in BRCA1 or BRCA2 genes are implicated in approximately 15% of ovarian cancers.1 Although this subset of ovarian cancers is generally characterized by a good initial response to chemotherapy, 10-year survival is not different between those with BRCA1/2 mutations and noncarriers.2 In a retrospective analysis of 212 women with relapsed high-grade serous ovarian cancer between 2000 and 2014, Sokolenko and colleagues sought to further evaluate the distinguishing clinical features between hereditary and sporadic ovarian cancer.3

Of the included patients, 113 (53.3%) and 99 (46.7%) underwent complete primary or interval surgical debulking, respectively. Most women (n = 146; 68.9%) were negative for BRCA1/2 germ-line mutations, whereas 66 (31.1%) were carriers of BRCA1/2 mutations. As the investigators expected, the median platinum-free interval (PFI) in BRCA1/2 carriers was longer compared with sporadic cases (13.2 months vs 8.0 months; P <.001). Furthermore, the proportion of ovarian cancer cases with PFI >12 months was significantly higher among BRCA1/2 carriers (38/66 [58%]) compared with patients with sporadic disease (51/146 [35%]; P = .003).

Looking at relapse location, no statistical between-group difference was observed in the frequency of relapses to distant locations (P = .4). However, systemic recurrences (ie, multiple lesions) occurred significantly more frequently in sporadic cases (98/144 [68%]) compared with carriers of BRCA1/2 mutations (30/60 [50%]; P = .02) and were associated with a shorter PFI (P = .003). In addition, a greater proportion of BRCA1/2 mutation carriers than noncarriers could be subjected to local treatment (locoregional discrete recurrence with lymphatic/transcoelomic spread) (29/66 [44%] vs 45/146 [31%], respectively; P = .045).

Taken together, the results of this study indicate that ovarian cancers driven by BRCA1/2 are characterized by a more favorable mode of relapse than sporadic high-grade serous ovarian cancers.


References

  1. Pan Z, et al. Oncotarget. 2017;8(57):97657-97670.
  2. Huang YW. Medicine. 2018;97:2(e9380).
  3. Sokolenko AP, et al. ESMO 2018. Abstract 991P.
Related Items
Multicancer Early Detection Blood Test May Change Cancer Screening Paradigms
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Overcoming Challenges in the Treatment of Primary Brain Tumors
William King
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Promising New Approach to Treating Patients with Desmoid Tumors
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
5-Year Follow-Up Study Confirms Safety and Efficacy of Trastuzumab Biosimilar in Patients with HER2-Positive Breast Cancer
William King
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ESMO
Bevacizumab Biosimilar Demonstrates Therapeutic Equivalence to Reference Drug in Patients with Late-Stage NSCLC
Anne Rowe
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ESMO
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives published on February 24, 2020 in ESMO
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Adjuvant Innovative Peptide Vaccine Therapy Shows Promising Activity in Early-Stage Triple Negative Breast Cancer
Conference Correspondent  published on November 5, 2018 in ESMO 2018 Wrap Up, ESMO
Breaking News from the 2018 Meeting of the European Society for Medical Oncology (ESMO)
Conference Correspondent  published on October 22, 2018 in ESMO 2018 Wrap Up, ESMO
Last modified: July 22, 2021